Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Reporting date: February 9, 2022. The filing reports positive topline results from the Phase 2 PHALCON-NERD study of vonoprazan for episodic heartburn in patients with non-erosive gastroesophageal reflux disease (NERD), and provides an update on Phase 3 development plans.
Business Context and Study Period
PHALCON-NERD-201 was a U.S. multicenter, double-blind, placebo-controlled Phase 2 study with an open-label daily-dosing run-in phase and a six-week on-demand treatment phase. During the run-in, 458 participants received vonoprazan 20 mg once daily for up to four weeks. The on-demand phase randomized 207 participants across vonoprazan 10 mg, 20 mg, 40 mg, and placebo treatment arms.
Key Clinical and Operating Metrics
| On-demand dose | Evaluable episodes | Complete and sustained relief within 3 hours | P-value |
|---|---|---|---|
| Placebo | 370 | 27.3% | Not applicable |
| Vonoprazan 10 mg | 359 | 56.0% | <0.0001 |
| Vonoprazan 20 mg | 327 | 60.6% | <0.0001 |
| Vonoprazan 40 mg | 323 | 70.0% | <0.0001 |
- All three vonoprazan doses met the primary endpoint and were statistically superior to placebo.
- During the daily-dosing run-in, the mean percentage of 24-hour heartburn-free days was 65.4%; the median was 76.0%.
- Vonoprazan was generally well tolerated. No adverse event occurred in more than 3% of participants in any treatment group.
- Four serious adverse events occurred during the daily-dosing phase and none during the on-demand phase. Safety results were described as comparable to placebo and consistent with prior studies.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other corporate financial metrics.
Material Changes and Outlook
- Phathom initiated NERD-301, a Phase 3 study evaluating vonoprazan 10 mg and 20 mg once daily for NERD.
- Management expects to report topline NERD-301 results in 2023.
- Based on the Phase 2 on-demand results, the Company plans to discuss with the FDA a Phase 3 design supporting vonoprazan as an on-demand treatment for episodic heartburn in NERD.
- The Company plans to present full Phase 2 results at a future medical meeting.
Risks, Contingencies, and Unusual Items
- The reported topline results are preliminary and remain subject to audit and verification, which could materially change the final efficacy or safety data.
- FDA disagreement with the Company’s interpretation of the data could delay or prevent the planned Phase 3 on-demand program.
- Development and commercialization remain subject to regulatory approval, future efficacy and safety results, manufacturing and clinical-trial execution, third-party dependence, intellectual property and license-compliance matters, and potential COVID-19-related disruptions.
- Unexpected adverse effects or inadequate efficacy could limit development, approval, or commercialization and could lead to recalls or product-liability claims.
- The filing’s forward-looking statements are subject to additional risks described in the Company’s SEC filings.
Facts Investors Should Verify
- Final audited results from PHALCON-NERD-201, including any changes from the preliminary topline analysis.
- FDA feedback and the design, timing, and enrollment of the proposed on-demand Phase 3 study.
- Enrollment progress and topline results for NERD-301, expected in 2023.
- Regulatory, manufacturing, intellectual-property, licensing, and safety developments affecting vonoprazan.
- The Company’s financial position and funding runway, which are not addressed in this filing.